I already have one basic question that someone here might be able to help with:
According to the company website, the COLT trial was to assess the safety and efficacy of CaPre in mild-to-severe hypertriglyceridemic patients. And the TRIFECTA trial is to assess the safety and efficacy of CaPre in mild-to-severe hypertriglyceridemic patients.